Creating the next generation of biologics

Covagen AG (acquired by Johnson & Johnson)

Incorporated

07.01.2007

Headquarters

Zürich-Schlieren

Support

Covagen is a privately held company pioneering the commercialization of Fynomers as next generation protein drugs to address unmet medical needs in inflammatory diseases and cancer. Fynomers represent a novel class of protein therapeutics. Due to their favorable biophysical properties, Fynomers with different binding specificities can be combined in a single molecule, thus creating drugs with new mechanisms of action.